Biofrontera Inc. Announces Closing of $9.4 Million Private Placement
May 19, 2022 09:48 ET
|
Biofrontera Inc.
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the...
Biofrontera Inc. Announces Pricing of $9.4 Million Private Placement
May 16, 2022 08:00 ET
|
Biofrontera Inc.
WOBURN, MA., May 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera, Inc. (Nasdaq: BFRI; BFRIW), announced today that it has entered into a securities purchase agreement with a single institutional investor...
Biofrontera Inc. Announces Participation in Two Dermatology Conferences in January
January 10, 2022 08:45 ET
|
Biofrontera Inc.
WOBURN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products,...
Biofrontera Inc. announces reduction of Biofrontera AG shareholding to less than 50% through warrant exercises
December 30, 2021 08:45 ET
|
Biofrontera Inc.
WOBURN, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced that through...
Biofrontera Inc. Enrolls First Subject in Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz®
December 06, 2021 09:00 ET
|
Biofrontera Inc.
WOBURN, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Biofrontera AG announces initiation of clinical studies
November 16, 2021 09:01 ET
|
Biofrontera AG
Leverkusen, Germany, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that two...
Biofrontera AG receives FDA-approval of the BF-RhodoLED® XL lamp
October 22, 2021 09:55 ET
|
Biofrontera AG
Leverkusen, Germany, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced the...
Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland
July 23, 2021 04:15 ET
|
Biofrontera AG
Leverkusen, Germany, July 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Medac Gesellschaft für...
Biofrontera AG reports completion of the clinical phase of the pharmacokinetics study
October 08, 2020 11:04 ET
|
Biofrontera AG
Leverkusen, Germany, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, reports the...
Biofrontera starts patient recruitment for U.S. Phase III Trial Evaluating Ameluz® / BF-RhodoLED® for Superficial Basal Cell Carcinoma
September 26, 2018 03:15 ET
|
Biofrontera AG
Enrollment of 186 patients at 12 study sites in the U.S. startedPhase III trial completion for photodynamic therapy of superficial basal cell carcinoma expected in first half of 2020Filing for...